Antibody-based therapeutics in oncology

References

• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256,495–497 (1975).
   PubMed Web of Science ®Google Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nature Rev Cancerl, 118–129 (2001).
   Google Scholar
• Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 43,693–713 (2002).
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of radiolabelledantibody production, safety testing and clinical trials.
   Google Scholar
• Posey JA, Khazaeli MB, Bookman MA et al. A Phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin. Cancer Res. 8,3092-3099 (2002).
   Google Scholar
• Reichert JM. Monoclonal antibodies in the clinic. Nature Biotecbnol 19,819–822 (2001).
   PubMed Web of Science ®Google Scholar
• ••Overview of anticancer antibodies in bothearly-stage development and on the market.
   Google Scholar
• Hemminki A. From molecular changes to customised therapy. Eur.j Cancer38, 333–338 (2002).
   PubMed Web of Science ®Google Scholar
• Reilly PM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical an pharmacokinetic solutions. Clin. Pbarmacokinet 28,126–142 (1995).
   Google Scholar
• Winter G, Harris WJ. Humanized antibodies. Immunol Today14,243–246 (1993).
   PubMedGoogle Scholar
• Merluzzi S, Figini M, Colombatti A, Canevari S, Pucillo C. Humanized antibodies as potential drugs for therapeutic use. Adv Clin. Path. 4,77–85 (2000).
   Google Scholar
• Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1,365–372 (1994).
   Google Scholar
• Pimm MV. Possible consequences of human antibody responses on the biodistribution of fragments of human, humanized or chimeric monoclonal antibodies: a note of caution. Life Sci. 55, 45–49 (1994).
   Web of Science ®Google Scholar
• Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321,522–525 (1986).
   Google Scholar
• Isaacs JD. From bench to bedside: discovering rules for antibody design and improving serotherapy with monoclonal antibodies. Rbeumatology 40, 724–738 (2001).
   PubMed Web of Science ®Google Scholar
• Watkins NA, Ouwehand WH. Introduction to antibody engineering andphage display. VoxSang. 78,72–79 (2000).
   Google Scholar
• Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 9,152–166 (2002).
   Google Scholar
• ••Summarizes the current and futurecapabilities of antibody therapies for lymphomas and leukemias.
   Google Scholar
• Chester KA, Hawkins RE. Clinical issues in antibody design. Trend s Biotechnol 13, 294–300 (1995).
   PubMed Web of Science ®Google Scholar
• Reilly PM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stem H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin. Pbarmacokinet 28,126–142 (1995).
   Google Scholar
• Nielsen UB, Marks JD. Internalizing antibodies and targted cancer therapy: direct selection from phage display libraries. PSTT3, 282–291 (2000).
   PubMedGoogle Scholar
• Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control 9,106–113 (2002).
   PubMedGoogle Scholar
• Linenberger ML, Maloney DG, Bernstein ID. Antibody-directed therapies for hematological malignancies. Trend s Mol Med 8,69–76 (2002).
   PubMedGoogle Scholar
• Stevenson GT, Anderson VA, Leong WS. Engineered antibody for treating lymphoma. Recent Results Cancer Res 159, 104–112 (2002).
   PubMedGoogle Scholar
• Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a Phase II multicenter trial. Blood 99,4336–4342 (2002).
   PubMed Web of Science ®Google Scholar
• Dillman RO. Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 9,71–80 (2001).
   PubMedGoogle Scholar
• Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. Semin Oncol. 29(1 Suppl. 2), 105–112 (2002).
   Google Scholar
• Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas SeminOncol. 29(1 Suppl. 2) 30–35 (2002).
   Google Scholar
• ••Succinct overview of the mostcommercially successful antibody therapeutic yet developed.
   Google Scholar
• Grillo-Lopez AJ. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Expert Rev Anticancer Tiler. 2(3), 23–29 (2002).
   Google Scholar
• Krasner C, Joyce RM. Zevalin: °Yttrium labeled antiCD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. CUR: Pbarm. Biotechnol 2, 341–349 (2001).
   Google Scholar
• Gordon LI, Witzig TE, Wiseman GA et al Yttrium° ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non—Hodgkin's lymphoma. Semin Oncol. 29(1 Suppl. 2), 87–92 (2002).
   Google Scholar
• Wagner HN Jr, Wiseman GA, Marcus CS et al. Administration guidelines for radioimmunotherapy of non-Hodgkin'slymphoma with 90Y-labeled anti CD20 monoclonal antibody. J. Nucl. Med. 43, 267–272 (2002).
   Google Scholar
• Stadtmauer EA. Trials with gemtuzumab ozogamicin (I\Aylotare) combined with chemotherapy regimens in acute myeloid leukemia. Clin. Lymphoma 2 (Suppl. 1) S24-28 (2002).
   Google Scholar
• Nabhan C, Tallman MS. Early Phase I/II trials with gemtuzumab ozogamicin (Mylotargq in acute myeloid leukemia. Clin. Lymphoma 2\(Suppl. 1) S19-23 (2002).
   Google Scholar
• Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr. Opin. Oncol 13,522-527 (2001). Overview of the first antibody conjugated with a plant toxin to achieve regulatory approval.
   Google Scholar
• Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7,1490–1496 (2001).
   PubMed Web of Science ®Google Scholar
• Dumont FJ. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond. Expert Rev Anticancer The]: 2,23–35 (2002).
   PubMedGoogle Scholar
• Pangalis GA, Dimopoulou MN, Angelopoulou MK et al CAMPATH-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med. awl. 18,99-107 (2001).
   Google Scholar
• Carswell CI, Plosker GL, VVagstaff AJ. Daclizumab: a review of its use in the management of organ transplantation. Biothugs 15,745–773 (2001).
   Google Scholar
• Kreitman RJ, Chaudhary VK, Kozak RVV, FitzGerald DJ, Waldman TA, Pastan I. Recombinant toxins containing the variable domains of the antiTac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood 80,2344–2352 (1992).
   PubMed Web of Science ®Google Scholar
• Leonard JP, Link BK. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an antiCD22 monoclonal antibody) and Hu1D10 (apolizumab). Semin. 0401 29(1 Suppl. 2), 81–86 (2002).
   Google Scholar
• Cheson BD. Hematologic malignancies: new developments and future treatments. Semin. Oncol. 29(4 Suppl. 13), 33–45 (2002).
   Google Scholar
• Stockmeyer B, Schiller M, Repp R et al. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hul D10 — a humanized human leucocyte antigen DR antibody. Br Ilaematol 118,959–967 (2002).
   PubMed Web of Science ®Google Scholar
• Rutar FJ, Augustine SC, Kaminski MS, Wahl RL, Siegel JA, Cokher D. Feasibility and safety of out-patient Bexxar therapy (tositumomab and iodine 1131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members. Clin. Lymphoma 2,164–172 (2001).
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 235,177-182 (1987). Seminal study first finking HER-2/neu gene amplification to adverse outcome in breast cancer.
   Google Scholar
• Ross JS, Fletcher JA. HER-2/neu (c-erb- B2) gene and protein in breast cancer. Am. Clin. Pathol 112(1 Suppl. 1) S53-67 (1999).
   Google Scholar
• Huston JS, George AJ. Engineered antibodies take center stage. Hum Antibodies 10,127–142 (2001).
   PubMedGoogle Scholar
• Slamon DJ, Leyland-Jones B, Shak S et a/Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl. Med 344,783-92 (2001). Results of the trastuzumab pivot trial.
   Google Scholar
• Roche PC, Ingle JN. Increased HER2 with US Food and Drug Administration-approved antibody.j Clin. Oncol 17(1), 434 (1999).
   Google Scholar
• Paik S, Bryant J, Tan-Chiu E et al. Real- world performance of HER2 testing-ational Surgical Adjuvant Breast and Bowel Project experience. Natl Cancer Inst. 94,852–854 (2002).
   Google Scholar
• Press ME, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. 15,2894-2904 (1997).
   Google Scholar
• Mass RD, Press ME, Anderson S, Murphy M, Slamon DJ. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc. Ann. Clin. awl. 85 (2001).
   Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.j Clin. 0401 20,719-726 (2002).
   Google Scholar
• Dandachi N, Dietze 0, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 82,1007-1014 (2002).
   Google Scholar
• Bast RC Jr, Ravdin P, Hayes DF et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines for the American Society of Clinical Oncology. Oncol 19,1865-1878 (2001).
   Google Scholar
• Piccart-Gebhart MJ. Herceptin: the future in adjuvant breast cancer therapy. Anticancer Drugs 12\(Suppl. 4) S27-33 (2001).
   Google Scholar
• Ligibel JA, Winer ER Trastuzumab/ chemotherapy combinations in metastatic breast cancer. Semin. Oncol 29(3 Suppl. 11), 38–43 (2002).
   Google Scholar
• Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin. Oncol. 28(6 Suppl. 18) 43–47 (2001).
   Google Scholar
• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19,6550–6565 (2000).
   PubMed Web of Science ®Google Scholar
• Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. Cancer 37\(Suppl. 4) S16-22 (2001).
   Google Scholar
• Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol 29(1 Suppl. 4) 27-36(2002).
   Google Scholar
• Leonard DS, Hill AD, Kelly L, Dijkstra B, McDermott E, O'Higgins NJ. Antihuman epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br. Surg. 89,262-271 (2002).
   Google Scholar
• Reynolds T Biotech firm faces challenges from FDA, falling stock prices. J. Natl Cancer Inst. 94,326-328 (2002). Controversy concerning the FDA approval status of cetuximab.
   Google Scholar
• Rosen LS. Angiogenesis inhibition in solid tumors. Cancer. 7\(Suppl. 3) S120-128 (2001).
   Google Scholar
• Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9(2 Suppl), 36–44 (2002).
   PubMedGoogle Scholar
• Chen HX, Gore-Langton RE, Cheson BD. Clinical trials referral resource: Current clinical trials of the antiVEGF monoclonal antibody bevacizumab. Oncology15,1017, 1020, 1023-1026 (2000).
   Google Scholar
• Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit. Rev Oncol Hematol 40,17–24 (2001).
   PubMed Web of Science ®Google Scholar
• Haller DG. Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer. Semin. 28(1 Suppl. 1), 25–30 (2001).
   Google Scholar
• Kirchner EM, Gerhards R, Voigtmann R Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A-positive disseminated tumour cells. Ann. Oncol 13, 1044–1048 (2002).
   Google Scholar
• Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Oncol 17, 2889–2885 (1999).
   Web of Science ®Google Scholar
• Kindler HL, Shulman KL. Metastatic colorectal cancer. Cur. r .7ieat. Options Oncol 2(6), 459–471 (2001).
   Google Scholar
• Indar A, Maxwell-Armstrong CA, Durrant LG, Carmichael J, Scholefield JH. Current concepts in immunotherapy for the treatment of colorectal cancer. J. R. Coll Surg. Filinb. 47,458–474 (2002).
   PubMedGoogle Scholar
• Valone FH, Kaufman PA, Guyre PM et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. j Clin. Oncol. 13,2281-2292 (1995).
   Google Scholar
• Curnow RT. Clinical experience with CD64-directed immunotherapy. An overview. Cancer ImmunolImmunother. 45, 210–215 (1997).
   Google Scholar
• Holmes EH. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin. Investig Drugs10, 511–519 (2001).
   PubMed Web of Science ®Google Scholar
• Liu H, Moy P, Kim S et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57,3629–3634 (1997).
   PubMed Web of Science ®Google Scholar
• Bander NH, Nanus D, Goldsmith S et al Phase I trial of humanized monoclonal antibody (mAb) top prostate specific membrane antigen/extracellular domain (PSMAext). Proc. Ann. Soc. Clin. Oncol 722 (2002).
   Google Scholar
• Mulders PF, De Mulder PH. The role of adjuvant immunotherapy in renal cell carcinoma. CUIT: Urol Rep 3,44–9 (2002).
   PubMedGoogle Scholar
• Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM. Antirenal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother. 51,171–177 (2002) .
   PubMed Web of Science ®Google Scholar
• Foon KA, Lutzky J, Baral RN et al Clinical and immune responses in advanced melanoma patients immunized with an antiidiotype antibody mimicking disialoganglioside GD2. j Clin. Oncol. 18, 376–384 (2000).
   Google Scholar
• Bier H, Hoffmann T, Hauser U et al. Clinical trial with escalating doses of the anti-epidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother. Phannacol 47,519–524 (2001).
   Google Scholar
• Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin. Oncol 29(1 Suppl. 4), 47–50 (2002).
   Google Scholar
• Rowinsky EK, Ochoa L, Patnaik A et al. SB-408075, a tumor-activated immunoconjugate targeting the C242 CanAg antigen with a potent maytansinoid payload; Phase 1, pharmacokinetic (PK) and biological studies. Proc. Ann. Soc. Clin. Oncol. 118 (2002).
   Google Scholar
• Fossella FV, Tokher A, Elliott M et al.. Phase 1 trial of the monoclonal antibody conjugate BB-10901, for relapsed/ refractory small cell lung cancer (scLq and other neuroendocrine (NE) tumors. Proc. Ann. Soc. Clin. awl. 1232 (2002).
   Google Scholar